Navigation Links
CardioGenics to be Spotlighted in Three Publications During Month of April
Date:4/22/2010

MISSISSAUGA, Ontario, April 22 /PRNewswire-FirstCall/ -- CardioGenics Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the immunoassay segment of the IVD testing market, will be spotlighted in three publications during the month of April: Today's Medical Developments, Medical Design Technology and The Wall Street Transcript.

In the April 2010 print and online editions of Today's Medical Developments, senior editor Elizabeth Engler Modic contributes an article titled "Going from Hours Down to Minutes Saves Lives." In the article, Modic describes the QL Care analyzer, a sensitive and accurate point-of-care (POC) analyzer, which was conceived and developed by a team led by CardioGenics founder and CEO Yahia Gawad, Ph.D. Gawad comments on the market need for a new POC analyzer that can reduce the time required to diagnose a cardiac event and other conditions, outlines the prototyping and testing phases, describes its advantages over existing products, and summarizes future steps leading up to its commercial release.    

In the April 2010 print and online editions of Medical Design Technology, Dr. Gawad contributes an article titled "The QL Care Analyzer: A Leap Forward in POC Diagnostics." In the article, Gawad delves into the physical characteristics and technical operation of the QL Care analyzer. For example, he describes the device's use of patent-protected disposable test cartridges and its use of chemiluminescence to derive test results. The analyzer's memory processor, touch LCD screen, and internal printer are among the additional features he describes.

In a Q&A posted on The Wall Street Transcript website on April 5, 2010, Dr. Gawad provides a brief history of CardioGenics, describes why he chose to enter the In Vitro Diagnostics market, and provides additional details on the status of the QL Care analyzer. He highlights some of the challenges of securing the medical community's acceptance of new technology and of doing business during a time when US healthcare options are being dramatically overhauled.      

Dr. Gawad remarked: "As CardioGenics continues to grow and to prepare its products for market, we welcome media attention that focuses on what we have to offer the healthcare community. We believe our QL Care analyzer and other products offer the possibility of saving many lives, and such exposure allows potential customers to become aware of our technology and how it could serve their patients."

To read the Today's Medical Developments article, please visit: http://www.onlinetmd.com/tmd-0410-test-results-improves-diagnosis.aspx

To read the Medical Design Technology article, please visit:  

http://e-ditionsbyfry.com/Olive/ODE/MDT/ and click on p. 20 in the Table of Contents

To read an excerpt of The Wall Street Transcript Q&A, please visit:

www.twst.com

About CardioGenics Holdings Inc.

Through its CardioGenics subsidiaries, the Company develops technology and products targeting the immunoassay segment of the In-Vitro Diagnostic testing market. It has developed the QL Care Analyzer, a proprietary Point Of Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada.

Safe Harbor Statement

Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "Anticipate, "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.


'/>"/>
SOURCE CardioGenics Holdings Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CardioGenics Holdings Inc. Provides Update on FINRA Submission Regarding Name Change
2. CardioGenics Holdings Inc. Announces Letter to Shareholders
3. CardioGenics Announces Completion of Cartridge Design for QL Care Analyzer
4. CardioGenics Holdings Inc. Featured in Medical Device Daily
5. Dr. Yahia Gawad, CEO of CardioGenics Holdings, Inc., Interviewed in MedTech Executive
6. CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads
7. CardioGenics Announces Further Update Regarding Status of Merck Agreement
8. CardioGenics Announces Lock-Up Agreement with Dr. Yahia Gawad
9. ViroPharma to Present at Three Upcoming Healthcare Conferences
10. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
11. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology:
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/27/2016)... ... ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, an ... United States and Canada wear eyeglasses. Once considered to be a purely functional part ... fashion statement. Even celebrities use glasses as a way of creating an iconic image—like ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, ... Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility ... home to some of the world’s leading providers of cereal and other breakfast foods. ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
Breaking Medicine News(10 mins):